Skip to content

    Solara Active

    SOLARA
    Healthcare·15 May 2026
    Management Summary

    Solara Active Pharma Sciences reported a robust Q4 FY26, marking its best performance in eight quarters across key financial metrics, primarily driven by its high-margin base business. The company made significant strides in debt reduction and revitalized its R&D pipeline. However, the ibuprofen business remains a drag, with its strategic future still pending a decision in the coming quarters.

    Highlights

    5

    • Achieved highest revenue, gross margins, and EBITDA in the previous 8 quarters.

    • Overall business demonstrated a strong sequential growth of 12% Q-o-Q in revenue and 65% Q-o-Q in EBITDA.

    • Base business continues to gain momentum, operating at a 26% EBITDA margin with 54% gross margins.

    • Successfully reduced debt by approximately INR 158 crores during FY26, with a line of sight to further reduce to INR 503 crores by May '26.

    • Reignited R&D engine with a plan to file 4-5 DMFs every year, expecting impactful revenues by FY29-FY30.

    Concerns

    3

    • Ibuprofen business continues to face persistent headwinds and recorded a negative EBITDA, eating into overall profitability.

    • Strategic options for the ibuprofen business are still under evaluation by bankers, with a conclusion expected in H1 FY27, causing delays in other strategic initiatives.

    • The carve-out of polymers in the CRAMS business has been put on hold until the ibuprofen strategic options are finalized.

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹392 Cr+12%QoQ
    2. 02Gross Margins47%
    3. 03Gross Value₹184 Cr
    4. 04EBITDA₹61 Cr+65%QoQ
    5. 05EBITDA Margin16%

    Segment breakdown

    Developed Markets
    75% Contribution to Sales
    CRAMS Business
    ₹10 Cr Annual Revenue
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net ₹503 crores

    Guidance & targets

    7
    CategoryTargetPriority
    Profitability
    Base Business EBITDA Margin
    25% plus
    		High
    Debt
    Debt Reduction
    INR 503 crores
    		High
    Debt
    Debt-Free Status
    Debt-free
    		High
    Product Pipeline
    DMF Filings
    four to five DMF filings
    		High
    Product Pipeline
    R&D Impact on Revenues/Margins
    impactful revenues and margins
    		Medium
    Strategic Options
    Ibuprofen Strategic Options Conclusion
    conclusion
    		High
    Capacity
    Vizag Facility Roadmap
    clear road map
    		High

    Conclusion of Ibuprofen strategic options

    H1 of this financial year
    CurrentUnder evaluation by bankers
    TargetConclusion announced

    Why it matters

    Resolution of the ibuprofen business is crucial for improving overall profitability and strategic focus.

    But I believe we'll be in a better position to put out the conclusion on this strategic piece in H1 of this financial year.

    How to verify

    guidance_and_targets[category='Strategic Options', metric='Ibuprofen Strategic Options Conclusion']

    Risks & concerns

    3
    RiskSeverity

    Ibuprofen business being a drag on overall profitability

    The ibuprofen business continues to face headwinds and recorded a negative EBITDA, eating into the company's overall EBITDA. — Management acknowledged

    high

    Lack of new product filings from R&D in recent years

    The R&D engine has not been able to come up with at least one new product filing in the last 4 years, impacting future pipeline. — Management acknowledged

    medium

    Commodity nature of ibuprofen business requiring significant investment for limited returns

    Ibuprofen is a commodity business that has continuously generated negative EBITDA, making further investment less attractive compared to the high-margin base business. — Management acknowledged

    high

    Q&A highlights

    8

    “No, no, no, Sajal. There's nothing one-off there. And like always, our story continues despite all the headwinds we are facing and the money that we are losing on the ibuprofen business, I think our base business is what's driving the momentum is what's keeping the tailwinds also. Again, coming back to your question, there's no one-off here.”

    Clarifies that the strong Q4 performance is driven by sustainable momentum from the base business, not one-off events.

    asked by Sajal Kapoor

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Q4 FY26 Financial Performance

    Solara Active Pharma Sciences delivered its best quarterly performance in eight quarters, with revenue reaching INR 392 crores, a 12% sequential growth. Gross margins improved by 170 basis points Q-o-Q to 47%, translating to an absolute gross value of INR 184 crores. The company's EBITDA surged by 65% Q-o-Q to INR 61 crores, achieving an EBITDA margin of 16%.

    02

    Base Business as Key Growth Driver

    The robust Q4 performance was primarily fueled by the base business, which continues to demonstrate strong momentum and superior profitability. This segment operates with a healthy 26% EBITDA margin and 54% gross margins. The company's focus on sustainable, profitable growth is reinforced by the base business, with developed markets contributing 75% of overall sales.

    03

    Strategic Review of Ibuprofen Business

    The ibuprofen business remains a significant challenge, recording negative EBITDA and acting as a drag on overall profitability. Solara has engaged bankers to evaluate strategic options for this segment, with a conclusion anticipated in the first half of the current financial year. This ongoing review has temporarily halted the planned carve-out of polymers within the CRAMS business.

    04

    Significant Debt Reduction Initiatives

    Solara made substantial progress in strengthening its balance sheet, reducing debt by approximately INR 158 crores during FY26. This reduction included INR 113 crores from the first call money of rights and INR 45 crores from operational cash flows. The company aims to further reduce its debt to approximately INR 503 crores by the end of May 2026 and has a long-term target of becoming debt-free by FY29.

    05

    Revitalized R&D and Product Pipeline

    After a period of no meaningful DMF filings in the past four years, Solara is reigniting its R&D efforts with a plan to file four to five DMFs annually, starting this year. This renewed focus on product development is expected to yield impactful revenues and margins, with the financial benefits projected to materialize around the FY29-FY30 timeframe, indicating a long-term growth strategy.

    06

    Capacity Utilization and Operational Efficiency

    The company currently utilizes about 70% of its existing capacity, providing approximately 30% spare capacity for future growth without requiring significant greenfield capex. Management is prioritizing debottlenecking projects and improving cycle times to enhance capacity for high-margin products, emphasizing operational efficiency and optimal use of working capital to drive growth.

    07

    Vizag Facility Status and Future Outlook

    The Vizag facility, commissioned in 2024, is currently mothballed and incurs an annual fixed cost expenditure of INR 12-15 crores. Its future utilization, whether for ibuprofen or other purposes, is dependent on the strategic review of the ibuprofen business. A clear roadmap for the Vizag facility is expected to be announced in the first half of the current financial year.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.